1. Scrip
  2. >>Conferences
  3. >>ASCO

Mirati Seeks Differentiation, Amgen Invests In Combos To Dominate KRAS G12C Field

Biomarker Data Confirm Amgen Strategy; Mirati’s Drug Works In CNS

 
• By Mandy Jackson

Amgen outlined the most frequent co-mutations in treatment-resistant lung and colorectal cancers at ASCO, while Mirati’s adagrasib showed efficacy in active CNS metastases in lung cancer patients. 

Business competition concept with Colorful paper ships on white background
Amgen was first to market but Mirati is close behind • Source: Shutterstock

Amgen, Inc. was the first to bring a KRAS G12C inhibitor to market with the US Food and Drug Administration approval of Lumakras (sotorasib) a year ago and Mirati Therapeutics, Inc. is on track for a second-place finish with potential FDA approval of adagrasib in December of this year. However, both companies still have a lot of work to do to illustrate the best use of their therapies and each attempted to advance that understanding at the American Society of Clinical Oncology meeting.

As Amgen vice president of late-stage oncology development I-Fen Chang noted in an interview with Scrip, “We're just at the tipping point of understanding which patients can benefit from KRAS...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

 
• By Alaric DeArment

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.

ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small

 
• By Alaric DeArment

The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 
• By Alaric DeArment

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

More from Conferences

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 
• By Alaric DeArment

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

ASCO Preview: Data From Regeneron, J&J/Legend And Others In Hematology

 
• By Alaric DeArment

With the American Society of Clinical Oncology meeting kicking off on 30 May, Scrip will follow the latest in blood cancers, including Regeneron’s linvoseltamab in multiple myeloma and Merck’s ADC zilovertamab vedotin in DLBCL.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.